二盐酸肼

• 分子结构分类: 无机化合物 - 均质非金属化合物 - 卤代有机物
• 中文名称: 二盐酸肼
• 中文别名: 盐酸联氨；联氨二盐酸盐；肼二盐酸盐；双盐酸肼；肼双盐酸盐
• 英文名称: hydrazine;hydron;dichloride
• 化学式: Cl2H6N2
• 分子量: 104.96
• InChiKey: LIAWOTKNAVAKCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.34
• 重原子数：
  4
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  4
• 氢受体数：
  2

ADMET

毒理性

• 副作用

神经毒素 - 其他中枢神经系统神经毒素 职业性肝毒素 - 继发性肝毒素：职业环境中潜在的有毒效应基于人类摄入或动物实验的中毒案例。 皮肤毒素 - 皮肤烧伤。 皮肤致敏剂 - 可以诱导皮肤过敏反应的剂。 有毒性肺炎 - 由于吸入金属烟雾或有毒气体和蒸气引起的肺部炎症。

Neurotoxin - Other CNS neurotoxin Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation. Dermatotoxin - Skin burns. Skin Sensitizer - An agent that can induce an allergic reaction in the skin. Toxic Pneumonitis - Inflammation of the lungs induced by inhalation of metal fumes or toxic gases and vapors.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

反应信息

• 作为反应物：
  描述：

  4-acetyl-3-methoxy-5-phenyl-5H-furan-2-one 、 二盐酸肼 以73%的产率得到
  参考文献：
  名称：

  KURIHARA, TAKUSHI;NASU, KEIKO;INOUE, MASATOSHI;ISHIDA, TOSHIMASA, CHEM. AND PHARM. BULL., 1983, 31, N 3, 912-918

  摘要：

  DOI：
• 作为试剂：
  描述：

  2-氯-6-甲氧基喹啉-3-甲腈 、 一水合肼 、 乙醇 在 二盐酸肼 、 N,N-二甲基甲酰胺 作用下， 反应 24.0h， 以to give 12.3 g 6-methoxy-1H-pyrazolo[3,4-b]quinolin-3-amine as a bright-yellow solid, m.p. >300° C.的产率得到6-methoxy-1H-pyrazolo[3,4-b]quinolines-3-amine
  参考文献：
  名称：

  Pyrazolo[3,4-b]quinolines and their use as antiviral agents

  摘要：

  具有以下式子的吡唑并[3,4-b]喹啉化合物##STR1## 其中R为氢，羟基或烷氧基; R.sub.2为卤素，氰基，氨基甲酸酯，羧基，低烷基羧酰基，氨基或氨甲基; R.sub.1为氢或如此定义的选择性取代基，可用作抗病毒剂和/或血管扩张剂。

  公开号：

  US04920128A1

文献信息

• PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Endo Pharmaceuticals Inc.

  公开号：US20140221315A1

  公开（公告）日：2014-08-07

  The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R 1 and R 2 are defined herein.

  本申请提供了新型嘧啶并吡啶嗪酮化合物以及制备和使用这些化合物的方法。通过向患者投药一种或多种化合物，这些化合物可用于治疗患者的炎症。在一种实施方式中，新型嘧啶并吡啶嗪酮化合物为公式（I）中的化合物，其中R1和R2在此定义。
• Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon
  申请人：Obshchestvo s ogranichennoy otvetstvennostyou "Fusion Pharma"

  公开号：US20140213592A1

  公开（公告）日：2014-07-31

  The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.

  本发明涉及使用新的化学化合物家族辅助治疗肿瘤、慢性炎症和类似疾病，这些化合物家族在抑制Abl激酶及其突变形式以及其他具有治疗意义的激酶方面具有提高的效率。本发明描述了蛋白激酶抑制剂，其形式为通式(I)和通式(II)的化合物，或其互变异构体、单个异构体、异构体混合物、药学上可接受的盐、溶剂或其水合物。
• Excitatory amino acid receptor antagonists and methods for the use
  申请人：Eli Lilly and Company

  公开号：US05153196A1

  公开（公告）日：1992-10-06

  Excitatory amino acid receptor antagonists and methods for the use thereof are disclosed. The antagonists include compounds having the preferred formula: ##STR1## in which: each of A.sub.1, A.sub.2 and A.sub.3 is independently either C or N, except that at least one of A.sub.1, A.sub.2 and A.sub.3 is N; one of A.sub.4 and A.sub.5 is C and the other is N; each R.sub.1 and R.sub.2 is independently hydrogen, halogen, CN, NO.sub.2, alkyl, aromatic, azido or CF.sub.3 ; and R.sub.3 is hydrogen, alkyl, aromatic or CF.sub.3. Also included are the tautomers thereof, and the pharmaceutically acceptable salts of (III) and (IV) and the tautomers thereof. These compounds are useful as EAA antagonists for blocking one or more EAA receptors, as neurological disorders associated with EAA receptors.

  本发明公开了兴奋性氨基酸受体拮抗剂及其使用方法。拮抗剂包括具有优选式的化合物：##STR1## 其中：A.sub.1，A.sub.2和A.sub.3中的每个独立地是C或N，但至少其中一个是N; A.sub.4和A.sub.5中的一个是C，另一个是N; 每个R.sub.1和R.sub.2独立地是氢，卤素，CN，NO.sub.2，烷基，芳香族，叠氮基或CF.sub.3; R.sub.3是氢，烷基，芳香族或CF.sub.3。还包括其互变异构体，以及（III）和（IV）及其互变异构体的药学上可接受的盐。这些化合物可用作EAA拮抗剂，用于阻断一个或多个EAA受体，以治疗与EAA受体相关的神经系统疾病。
• Heterarylpiperidine modulators of chemokine receptor activity
  申请人：Goble D. Stephen

  公开号：US20050250781A1

  公开（公告）日：2005-11-10

  The present invention is directed to compounds of the formula (I): (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 10 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

  本发明涉及以下式(I)的化合物：（其中R1，R2，R3，R4，R5，R6，R10和n在此定义），这些化合物可用作趋化因子受体活性的调节剂。特别地，这些化合物可用作趋化因子受体CCR-2的调节剂。
• Excitatory amino acid receptor antagonists in methods for the use thereof
  申请人：Eli Lilly and Company

  公开号：US05196421A1

  公开（公告）日：1993-03-23

  Excitatory amino acid receptor antagonists and methods for the use thereof are disclosed. The antagonists include compounds having the preferred formula: ##STR1## in which: each of A.sub.1, A.sub.2 and A.sub.3 is independently either C or N, except that at least one of A.sub.1, A.sub.2 and A.sub.3 is N; one of A.sub.4 and A.sub.5 is C and the other is N; each R.sub.1 and R.sub.2 is independently hydrogen, halogen, CN, NO.sub.2, alkyl, aromatic, azido or CF.sub.3 ; and R.sub.3 is hydrogen, alkyl, aromatic or CF.sub.3. Also included are the tautomers thereof, and the pharmaceutically acceptable salts of (III) and (IV) and the tautomers thereof. These compounds are useful as EAA antagonists for blocking one or more EAA receptors, as neuroprotective agents, and in the treatment of various neurological disorders associated with EAA receptors.

  本文公开了兴奋性氨基酸受体拮抗剂及其使用方法。这些拮抗剂包括具有以下首选式的化合物：##STR1##其中：A.sub.1、A.sub.2和A.sub.3中的每一个独立地是C或N，但至少有一个A.sub.1、A.sub.2和A.sub.3是N；A.sub.4和A.sub.5中的一个是C，另一个是N；每个R.sub.1和R.sub.2独立地是氢、卤素、CN、NO.sub.2、烷基、芳香基、偶氮基或CF.sub.3；而R.sub.3是氢、烷基、芳香基或CF.sub.3。还包括其互变异构体、(III)和(IV)及其互变异构体的药学上可接受的盐。这些化合物可用作EAA拮抗剂，用于阻断一个或多个EAA受体，作为神经保护剂，并用于治疗与EAA受体相关的各种神经系统疾病。

表征谱图